• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Layoff?

Quote
anonymous said:
Finally someone on this ridiculous board who is intelligent and can write. Agree with most of the points above. So the price for Medicare did come out: Jardiance current price of $537 to a Medicare negotiated price of $197 (ouch). BTW this starts in 2026. The Farxiga generic is absolute fact: Multiple generics coming out in October 2025 (a pharmacist in my are received a letter).
So the only possible prayer is that somehow generic Farxiga can be delayed through some sort of legal action (the government has been cracking down on this). Bottom line: How quickly does Farxiga penetrate the market and how soon does Zeeland pharma GLP1 take to come out? I agree with the author of this piece, there will be a BI sales force but there will be a reduction in numbers. This could happen as early as December 2024 or maybe 2Q 2025. When a generic comes out companies always cut the sales force. Not trying to scare anybody, just be realistic and do what's best for your career.
Click to expand...
Won’t be a true Farxiga generic until Q2 26 with a pediatric extension. And if it goes generic Q2 it won’t be multi sourced until probably Oct 26. Reps should worry about January 2027. My best guess is there will be some trims made and def deeper cuts by Q4 26 that are effective 1/1/27. A lot riding on pending launches for ILD, Mental Health and obesity, getting into the obesity market is gonna be a fight as Lilly and Novo have big head start and solid data.

As for the IRA MFP, BI dodged a big bullet. The ‘negotiated’ rebate could have been a lot closer to 70+% (which is where many commercial rebates are).
 




anonymous said:
Won’t be a true Farxiga generic until Q2 26 with a pediatric extension. And if it goes generic Q2 it won’t be multi sourced until probably Oct 26. Reps should worry about January 2027. My best guess is there will be some trims made and def deeper cuts by Q4 26 that are effective 1/1/27. A lot riding on pending launches for ILD, Mental Health and obesity, getting into the obesity market is gonna be a fight as Lilly and Novo have big head start and solid data.

As for the IRA MFP, BI dodged a big bullet. The ‘negotiated’ rebate could have been a lot closer to 70+% (which is where many commercial rebates are).
Click to expand...
are you saying the PBM will not receive a rebate on the new negotiated IRA price?
 
































































The second week of December they will give Warn Notifications and those reps will be done in February. It will be the same way that they handled the HSBS in December of 2022. Reps will have to work during Warn Period just like the respiratory and biosimilar reps did.
 




anonymous said:
The second week of December they will give Warn Notifications and those reps will be done in February. It will be the same way that they handled the HSBS in December of 2022. Reps will have to work during Warn Period just like the respiratory and biosimilar reps did.
Click to expand...
Who? Health System Teams and CRM reps?
 




anonymous said:
The second week of December they will give Warn Notifications and those reps will be done in February. It will be the same way that they handled the HSBS in December of 2022. Reps will have to work during Warn Period just like the respiratory and biosimilar reps
Click to expand...
December 2022 YL lead an ugly sweater Town Hall celebration the next day.
 




Top Bottom
Back
Quote